Diabetic Retinopathy and Ocular Melanoma: How far we are?

dc.contributor.authorSouto, Eliana B.
dc.contributor.authorCampos, Joana R.
dc.contributor.authorDa Ana, Raquel
dc.contributor.authorFangueiro, Joana F.
dc.contributor.authorMartins-Gomes, Carlos
dc.contributor.authorDurazzo, Alessandra
dc.contributor.authorLucarini, Massimo
dc.contributor.authorSánchez-López, E. (Elena)
dc.contributor.authorEspina García, Marta
dc.contributor.authorGarcía López, María Luisa
dc.contributor.authorSilva, Amélia M.
dc.contributor.authorMendonça, Fernando
dc.contributor.authorSantini, Antonello
dc.contributor.authorSouto, Selma B.
dc.date.accessioned2020-06-25T08:00:42Z
dc.date.available2020-06-25T08:00:42Z
dc.date.issued2020-04-16
dc.date.updated2020-06-25T08:00:42Z
dc.description.abstractDiabetic retinopathy causes vascular damage to retinal neurons, presenting characteristics of chronic inflammation. The development of new therapies capable of combating vision loss involves knowledge of inflammatory retinal changes. Studies in animal models and patients with diabetes have shown a high expression of the inflammatory molecules that are involved in the progression of diabetic retinopathy. Uveal melanoma is an eye tumour that remains highly deadly, because despite the correct treatment, it still causes metastasis in about 50% of patients. This type of tumour has the ability to produce and store melanin, which may result in resistance to therapy. Over time there has been development of new therapies for this disease, such as radiotherapy and surgical resection. In this review, we discuss diabetic retinopathy and ocular melanoma, their relationship with angiogenesis and the current anti-angiogenic therapies for their treatment
dc.format.extent28 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec701339
dc.identifier.issn2076-3417
dc.identifier.urihttps://hdl.handle.net/2445/166560
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/app10082777
dc.relation.ispartofApplied Sciences, 2020, vol. 10, p. 2777-
dc.relation.urihttps://doi.org/10.3390/app10082777
dc.rightscc-by (c) Souto, Eliana B. et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationAngiogènesi
dc.subject.classificationFactor de creixement de l'endoteli vascular
dc.subject.classificationRetinopatia diabètica
dc.subject.classificationMelanoma
dc.subject.classificationCeguesa
dc.subject.otherNeovascularization
dc.subject.otherVascular endothelial growth factors
dc.subject.otherDiabetic retinopathy
dc.subject.otherMelanoma
dc.subject.otherBlindness
dc.titleDiabetic Retinopathy and Ocular Melanoma: How far we are?
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
701339.pdf
Mida:
993.6 KB
Format:
Adobe Portable Document Format